J&J unit’s blockbuster gets new use.
ALKS 8700 may have fewer side effects than Tecfidera.
Amgen gets share of $1.5 billion deal
Company hopes to coach patients with stomach side-effects.
Analysts left guessing from snippet of early phase data.
Shire has bought rights to PF-00547659 for an undisclosed sum.
Antibodies against originator will also target biosimilar.